Investigational Alzheimer’s Therapy NNI-362 Receives FDA Approval to Enter Phase 1 Clinical Studies
Alzheimer's News, News
The U.S. Food and Drug Administration has approved Neuronascent’s investigational new drug (IND) application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a ... Read more